SOURCE Depomed, Inc.
The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."
A review of data produced by BoardEx reveals that many big and small activist-targeted corporate boards feature young directors in their early-to-mid 30s who work for insurgent fund managers
The company's new CEO tells analysts it continues to believe the novel painkiller Nucynta can be a blockbuster.
Depomed unveiled steps the company is taking to shore itself up.